Li Tingxuan, Luo Ran, Su Lina, Lv Feng, Mei Lin, Yu Yongkang
Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, P. R. China.
Department of Pharmacy, Qujing Medical College, Qujing, Yunnan, 655000, P. R. China.
Small Methods. 2023 Nov;7(11):e2300880. doi: 10.1002/smtd.202300880. Epub 2023 Aug 31.
Chimeric antigen receptor (CAR) cell therapy is a great success and breakthrough in immunotherapy. However, there are still lots of barriers to its wide use in clinical, including long time consumption, high cost, and failure against solid tumors. For these challenges, researches are deplored to explore CAR cells to more appliable products in clinical. This minireview focuses on the advanced non-viral materials for CAR-T transfection ex vivo with better performance, delivery systems combined with other therapy for enhancement of CAR-T therapy in solid tumors. In addition, the targeted delivery platform for CAR cells in vivo generation as a breakthrough technology as its low cost and convenience. In the end, the prospective direction and future of CAR cell therapy are discussed.
嵌合抗原受体（CAR）细胞疗法是免疫疗法的一项巨大成功和突破。然而，其在临床广泛应用仍存在诸多障碍，包括耗时久、成本高以及对实体瘤无效。针对这些挑战，研究人员致力于探索使CAR细胞在临床上更具适用性的产品。本综述聚焦于用于体外转染CAR-T的性能更优的先进非病毒材料、与其他疗法相结合以增强CAR-T在实体瘤治疗中效果的递送系统。此外，体内生成CAR细胞的靶向递送平台作为一项突破性技术，具有低成本和便利性。最后，还讨论了CAR细胞疗法的未来发展方向。
